Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.2 USD | -0.90% |
|
-14.06% | -27.87% |
06-25 | Needham Lowers Price Target on G1 Therapeutics to $6 From $12, Maintains Buy Rating | MT |
06-25 | HC Wainwright Lowers G1 Therapeutics Price Target to $3 From $9, Maintains Buy Rating | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company has a low valuation given the cash flows generated by its activity.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company sustains low margins.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-27.87% | 115M | C+ | ||
+16.45% | 122B | B+ | ||
+21.96% | 116B | B+ | ||
+23.73% | 27.03B | B | ||
-20.05% | 20.36B | B+ | ||
-16.28% | 15.91B | B | ||
-16.52% | 16.43B | A- | ||
-44.35% | 15.6B | A- | ||
+63.91% | 14.94B | C+ | ||
+2.52% | 13.59B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GTHX Stock
- Ratings G1 Therapeutics, Inc.